1. Home
  2. AVDL vs HIPO Comparison

AVDL vs HIPO Comparison

Compare AVDL & HIPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVDL
  • HIPO
  • Stock Information
  • Founded
  • AVDL 2015
  • HIPO 2015
  • Country
  • AVDL Ireland
  • HIPO United States
  • Employees
  • AVDL N/A
  • HIPO N/A
  • Industry
  • AVDL Biotechnology: Pharmaceutical Preparations
  • HIPO Property-Casualty Insurers
  • Sector
  • AVDL Health Care
  • HIPO Finance
  • Exchange
  • AVDL Nasdaq
  • HIPO Nasdaq
  • Market Cap
  • AVDL 861.4M
  • HIPO 694.3M
  • IPO Year
  • AVDL 1996
  • HIPO N/A
  • Fundamental
  • Price
  • AVDL $12.75
  • HIPO $28.83
  • Analyst Decision
  • AVDL Strong Buy
  • HIPO Strong Buy
  • Analyst Count
  • AVDL 7
  • HIPO 5
  • Target Price
  • AVDL $19.00
  • HIPO $34.40
  • AVG Volume (30 Days)
  • AVDL 1.2M
  • HIPO 167.7K
  • Earning Date
  • AVDL 08-07-2025
  • HIPO 08-06-2025
  • Dividend Yield
  • AVDL N/A
  • HIPO N/A
  • EPS Growth
  • AVDL N/A
  • HIPO N/A
  • EPS
  • AVDL N/A
  • HIPO N/A
  • Revenue
  • AVDL $221,075,000.00
  • HIPO $425,000,000.00
  • Revenue This Year
  • AVDL $56.78
  • HIPO $29.50
  • Revenue Next Year
  • AVDL $30.46
  • HIPO $21.85
  • P/E Ratio
  • AVDL N/A
  • HIPO N/A
  • Revenue Growth
  • AVDL 132.35
  • HIPO 43.15
  • 52 Week Low
  • AVDL $6.38
  • HIPO $15.74
  • 52 Week High
  • AVDL $17.30
  • HIPO $35.44
  • Technical
  • Relative Strength Index (RSI)
  • AVDL 76.98
  • HIPO 56.96
  • Support Level
  • AVDL $10.79
  • HIPO $24.75
  • Resistance Level
  • AVDL $14.23
  • HIPO $32.42
  • Average True Range (ATR)
  • AVDL 0.59
  • HIPO 1.35
  • MACD
  • AVDL 0.14
  • HIPO 0.39
  • Stochastic Oscillator
  • AVDL 61.15
  • HIPO 53.19

About AVDL Avadel Pharmaceuticals plc

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.

About HIPO Hippo Holdings Inc.

Hippo Holdings Inc is a home insurance group that created a new standard of care and protection for homeowners. It provides insurance for computers, home offices, electronics, appliances, water backup, and service line coverage, among others. It has three reportable segments Services segment earns fees and commission income without assuming underwriting risk or need for reinsurance, Insurance-as-a-Service managed through the company's subsidiary Spinnaker is a platform to support third-party MGAs, and the Hippo Home Insurance Program engaged in homeowners insurance business. It generates the majority of its revenue from the Insurance-as-a-Service segment.

Share on Social Networks: